CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $99.7 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.04 per share.

The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.92 per share.

The cancer drug developer posted revenue of $5.1 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $2.8 million.

Blueprint Medicines shares have risen 86% since the beginning of the year. The stock has climbed 68% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC

Sign up for Daily Newsletters Manage Newsletters

Copyright © 2020 The Washington Times, LLC.